219 related articles for article (PubMed ID: 10442507)
1. Patterns of potassium wasting in response to stepwise combinations of diuretics in nephrotic syndrome.
Haris A; Radó JP
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):332-40. PubMed ID: 10442507
[TBL] [Abstract][Full Text] [Related]
2. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
Radó JP; Sawinsky I; Juhos E
Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
[TBL] [Abstract][Full Text] [Related]
3. High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
Radó JP; Marosi J; Takó J
Endokrinologie; 1970; 57(1):46-62. PubMed ID: 4923990
[No Abstract] [Full Text] [Related]
4. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
Alcázar Arroyo R
Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of bumetanide in nephrotic syndrome: a double-blind crossover study with furosemide.
Lau K; DeFronzo R; Morrison G; Rascoff J; Goldberg M; Agus ZS
J Clin Pharmacol; 1976 Oct; 16(10 Pt 1):489-97. PubMed ID: 789411
[TBL] [Abstract][Full Text] [Related]
6. [The effect of albumin and furosemide administration in children with primary nephrotic syndrome (author's transl)].
Rego Filho Ede A; Casoni W
Rev Bras Pesqui Med Biol; 1977; 10(5):299-304. PubMed ID: 594431
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of transtubular potassium gradient in the diuretic management of patients with cirrhosis and ascites.
Lim YS; Han JS; Kim KA; Yoon JH; Kim CY; Lee HS
Liver; 2002 Oct; 22(5):426-32. PubMed ID: 12390478
[TBL] [Abstract][Full Text] [Related]
8. Combination diuretic drug therapy.
Reubi FC
Cardiovasc Clin; 1971; 2(3):197-210. PubMed ID: 4950425
[No Abstract] [Full Text] [Related]
9. Co-administration of albumin-furosemide in patients with the nephrotic syndrome.
Ghafari A; Mehdizadeh A; Alavi-Darazam I; Rahimi E; Kargar C; Sepehrvand N
Saudi J Kidney Dis Transpl; 2011 May; 22(3):471-5. PubMed ID: 21566302
[TBL] [Abstract][Full Text] [Related]
10. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
11. Update of diuretics in the treatment of hypertension.
Padilla MC; Armas-Hernández MJ; Hernández RH; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):154-60. PubMed ID: 17414583
[TBL] [Abstract][Full Text] [Related]
12. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
13. [Potassium-sparing diuretics (spironolactone, triamterene, amylorid)].
Haris A; Radó J
Orv Hetil; 1996 Sep; 137(35):1907-14. PubMed ID: 8927344
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
15. Development of a test to evaluate the transtubular potassium concentration gradient in the cortical collecting duct in vivo.
West ML; Bendz O; Chen CB; Singer GG; Richardson RM; Sonnenberg H; Halperin ML
Miner Electrolyte Metab; 1986; 12(4):226-33. PubMed ID: 3762509
[TBL] [Abstract][Full Text] [Related]
16. Correlation between creatinine clearance and transtubular potassium concentration gradient in old people and chronic renal disease patients.
Musso C; Liakopoulos V; Stefanidis I; De Miguel R; Imperiali N; Algranati L
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):551-5. PubMed ID: 17951942
[TBL] [Abstract][Full Text] [Related]
17. [Clinical comparative trial of piretanide and furosemide in patients with advanced renal insufficiency. Drug levels and diuretic potency of single oral doses].
Heuer LJ; Machnik H; Studt J; Fink R
Arzneimittelforschung; 1983; 33(9):1318-21. PubMed ID: 6685516
[TBL] [Abstract][Full Text] [Related]
18. Influence of alternate-day prednisolone administration on urinary electrolyte excretion.
Kumagai H; Honda N; Hishida A
Miner Electrolyte Metab; 1985; 11(1):52-6. PubMed ID: 3974538
[TBL] [Abstract][Full Text] [Related]
19. Amiloride-sensitive and amiloride-insensitive kaliuresis in advanced chronic kidney disease.
Levy Yeyati N; Fellet A; Arranz C; Balaszczuk AM; Adrogué HJ
J Nephrol; 2008; 21(1):93-8. PubMed ID: 18264941
[TBL] [Abstract][Full Text] [Related]
20. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
